Oliver Thomas R, Lee Philip R, Lipton Helene L
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Room 403, Baltimore, MD 21205-1999, USA.
Milbank Q. 2004;82(2):283-354. doi: 10.1111/j.0887-378X.2004.00311.x.
This article examines the history of efforts to add prescription drug coverage to the Medicare program. It identifies several important patterns in policymaking over four decades. First, prescription drug coverage has usually been tied to the fate of broader proposals for Medicare reform. Second, action has been hampered by divided government, federal budget deficits, and ideological conflict between those seeking to expand the traditional Medicare program and those preferring a greater role for private health care companies. Third, the provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 reflect earlier missed opportunities. Policymakers concluded from past episodes that participation in the new program should be voluntary, with Medicare beneficiaries and taxpayers sharing the costs. They ignored lessons from past episodes, however, about the need to match expanded benefits with adequate mechanisms for cost containment. Based on several new circumstances in 2003, the article demonstrates why there was a historic opportunity to add a Medicare prescription drug benefit and identify challenges to implementing an effective policy.
本文考察了将处方药保险纳入医疗保险计划的努力历程。它识别了四十多年来政策制定中的几个重要模式。首先,处方药保险通常与更广泛的医疗保险改革提案的命运相关联。其次,政府分歧、联邦预算赤字以及寻求扩大传统医疗保险计划的人与倾向于让私人医疗保健公司发挥更大作用的人之间的意识形态冲突阻碍了行动。第三,2003年《医疗保险处方药、改进和现代化法案》的条款反映了早期错失的机会。政策制定者从过去的事件中得出结论,新计划的参与应该是自愿的,医疗保险受益人和纳税人分担成本。然而,他们忽视了过去事件中关于需要将扩大的福利与适当的成本控制机制相匹配的教训。基于2003年的几个新情况,本文阐述了为何存在增加医疗保险处方药福利的历史性机会,并确定了实施有效政策面临的挑战。